PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTSSalts of 1,5-diarylpyrazole-3-carboxamides and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.A compound selected from: butane- 1 -sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin- 1 -ylcarbamoyl)- 2H-pyrazol-3-yl]phenyl ester; l-(2,4-dichlorophenyl)-4-methyl-5-[4-(4,4,4-trifluorobutoxy)phenyl]-lH-pyrazole-3- carboxylic acid piperidin-1-ylamide; propane- 1 -sulfonic acid 4-[2-(2,4-dichloro-phenyl)-4-methyl-5-(piperidin-l- ylcarbamoyl)2H-pyrazol-3-yl]-phenyl ester; propane- 1 -sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(morpriolin-4-ylcarbamoyl)-2H-pyrazol-3-yl]phenyl ester;3,3,3-trifluoropropane-l-sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-l- ylcarbamoyl)-2H-pyrazol-3 -yljphenyl ester;4,4,4-trifluorobutane-l -sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-l- ylcarbamoyl)-2H-pyrazol-3-yl]phenyl ester; propane- 1 -sulfonic acid-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-l-ylcarbamoyl)-2H-pyrazol-3-yl]-2,6-difluorophenyl ester; propane-l-sulfonic acid 4-[2-(2,4-dichlorophenyl)-5-(piperidin-l-ylcarbamoyl)-2H- pyrazol-3-yl]phenyl ester; propane- 1 -sulfonic acid 4-[4-bromo-2-(2,4-dichlorophenyl)-5-(piperidin- 1 -ylcarbamoyl)-2H-pyrazol-3-yl]phenyl ester; methyl 1 - { [( 1 -(2,4-dichlorophenyl)-4-methyl-5- {4[(propylsulfonyl)oxy]phenyl} - IH- pyrazol-3-yl)carbonyl]amino}cyclopentanecarboxylate; carbonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidine- 1 -ylcarbamoyl)-2H- pyrazol-3-yl]-phenyl ester propyl ester;4-{l-(2,4-dichlorophenyl)-4-methyl-3-[(piperidin-l-ylamino)carbonyl]-lH-pyrazol-5- yl}phenyl thiophene-2-sulfonate;4- { 1 -(2,4-dichlorophenyl)-4-methyl-3-[(piperidin- 1 -ylamino)carbonyl]- lH-pyrazol-5- yljphenyl pyridine-3 -sulfonate; tert-bntyl [2-(4-{l-(2,4-dichlorophenyl)-4-methyl-3-[(piperidin-l-ylamino)carbonyl]-lH- pyrazol-5-yl}phenoxy)ethyl]ethylcarbamate; 4- { 1 -(2,4-dichlorophenyl)-4-methyl-3-[(piperidin-l -ylamino)carbonyl]- lH-pyrazol-5- yl}phenyl 3-methylbutane- 1 -sulfonate;4-{l-(2,4-dichlorophenyl)-4-methyl-3-[(piperidin-l-ylamino)carbonyl]-lH-pyrazol-5- yl}phenyl 3,3-dimethylbutane-l-sulfonate; l-(2,4-dichlorophenyl)-5-{4-[2-(l,3-dioxolan-2-yl)ethoxy]phenyl}-4-methyl-N-piperidin-1 -yl-lH-pyrazole-3-carboxamide; propane- 1 -sulfonic acid 4-[2-(2,4-dichloro-3-fluorophenyl)-4-methyl-5-(piperidin-l- ylcarbamoyl)-2H-pyrazol-3-yl]phenyl ester; and5-chlorothiophene-2-sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin- 1 - Q ylcarbamoyl)-2Η-pyrazol-3-yl]phenyl ester; in the form of a methanesulphonate salt, a hemi-l,5-naphthalenedisulphonate salt, a 1,2- ethanedisulfonic acid salt, a hydrochloride salt or a hydrogen sulphate salt but excluding pyridine-3 -sulfonic acid 4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin- 1 -ylcarbamoyl)-2H-pyrazol-3-yl]phenyl ester hydrochloride. 5
치료제로서의 피라졸 유도체 본 발명은, 1,5-디아릴피라졸-3-카르복스아미드의 염 및 이러한 화합물의 제조 방법, 비만, 정신과적 장애 및 신경계 장애의 치료에서의 상기 화합물의 용도, 상기 화합물의 치료적 사용 방법 및 상기 화합물을 함유하는 약학 조성물에 관한 것이다. 부탄-1-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 1-(2,4-디클로로페닐)-4-메틸-5-[4-(4,4,4-트리플루오로부톡시)페닐]-1H-피라졸-3-카르복실산 피페리딘-1-일아미드; 프로판-1-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)2H-피라졸-3-일]-페닐 에스테르; 프로판-1-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(모르폴린-4-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 3,3,3-트리플루오로프로판-1-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 4,4,4-트리플루오로부탄-1-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 프로판-1-술폰산-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]-2,6-디플루오로페닐 에스테르; 프로판-1-술폰산 4-[2-(2,4-디클로로페닐)-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 프로판-1-술폰산 4-[4-브로모-2-(2,4-디클로로페닐)-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 메틸 1-{[(1-(2,4-디클로로페닐)-4-메틸-5-{4[(프로필술포닐)옥시]페닐}-1H-피라졸-3-일)카르보닐]아미노}시클로펜탄카르복실레이트; 탄산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]-페닐 에스테르 프로필 에스테르; 4-{1-(2,4-디클로로페닐)-4-메틸-3-[(피페리딘-1-일아미노)카르보닐]-1H-피라졸-5-일}페닐 티오펜-2-술포네이트; 4-{1-(2,4-디클로로페닐)-4-메틸-3-[(피페리딘-1-일아미노)카르보닐]-1H-피라졸-5-일}페닐 피리딘-3-술포네이트; t-부틸 [2-(4-{1-(2,4-디클로로페닐)-4-메틸-3-[(피페리딘-1-일아미노)카르보닐]-1H-피라졸-5-일}페녹시)에틸]에틸카르바메이트; 4-{1-(2,4-디클로로페닐)-4-메틸-3-[(피페리딘-1-일아미노)카르보닐]-1H-피라졸-5-일}페닐 3-메틸부탄-1-술포네이트; 4-{1-(2,4-디클로로페닐)-4-메틸-3-[(피페리딘-1-일아미노)카르보닐]-1H-피라졸-5-일}페닐 3,3-디메틸부탄-1-술포네이트; 1-(2,4-디클로로페닐)-5-{4-[2-(1,3-디옥솔란-2-일)에톡시]페닐}-4-메틸-N-피페리딘-1-일-1H-피라졸-3-카르복스아미드; 프로판-1-술폰산 4-[2-(2,4-디클로로-3-플루오로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르; 및 5-클로로티오펜-2-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르 에서 선택되며, 피리딘-3-술폰산 4-[2-(2,4-디클로로페닐)-4-메틸-5-(피페리딘-1-일카르바모일)-2H-피라졸-3-일]페닐 에스테르 히드로클로라이드를 제외한, 메탄술포네이트 염, 헤미-1,5-나프탈렌디술포네이트 염, 1,2-에탄디술폰산 염, 히드로클로라이드 염 또는 황산수소염의 형태인 화합물.